Copanlisib治疗复发或难治性边缘区淋巴瘤的疗效与安全性
该研究报告了pan-I类PI3K抑制剂copanlisib在2期CHRONOS-1研究Part B中23例复发/难治性边缘区淋巴瘤患者的长期疗效与安全性。患者中位既往治疗线数为3,客观缓解率为78.3%,中位缓解持续时间17.4个月,中位无进展生存期24.1个月。常见不良事件包括疲劳、腹泻和一过性输注相关高血糖,安全性可控。
要点
- 复发/难治性边缘区淋巴瘤患者接受copanlisib的客观缓解率达78.3%。
- 中位无进展生存期为24.1个月,中位缓解持续时间17.4个月。
- 最常见3/4级不良事件为一过性输注相关高血糖和高血压。
核心结论
- Copanlisib在复发/难治性边缘区淋巴瘤中显示出强效、持久的抗肿瘤活性,且安全性可控。
研究设计与样本
- 2期CHRONOS-1研究Part B(NCT01660451)中复发/难治性边缘区淋巴瘤亚组,共23例患者。
- 患者接受静脉copanlisib 60 mg,28天周期第1、8、15天给药,中位治疗23周。
主要发现
- 客观缓解率为78.3%(18/23),其中完全缓解3例、部分缓解15例。
- 中位缓解持续时间为17.4个月,中位起效时间为2.1个月。
- 中位无进展生存期为24.1个月,中位总生存期未达到。
- 最常见全级别治疗中出现的不良事件为疲劳(52.2%,12/23)、腹泻和一过性输注相关高血糖(各47.8%,11/23)。
临床怎么用
- 对于既往接受过含利妥昔单抗和烷化剂治疗的复发/难治性边缘区淋巴瘤患者,copanlisib可作为一种有效的长期治疗选择。
局限性
- 该分析为2期研究中的亚组分析,样本量较小(23例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Marginal zone lymphoma (MZL) is challenging to treat, with many patients relapsing following initial treatment. We report the long-term efficacy and safety of copanlisib, a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, in the subset of 23 patients with relapsed/refractory MZL treated in the phase 2 CHRONOS-1 study (#NCT01660451, Part B; www.clinicaltrials.gov). Patients had a median of 3 prior lines of therapy, including rituximab and alkylating agents, and received IV copanlisib 60 mg on days 1, 8, and 15 of 28-day cycles for a median of 23 weeks. The objective response rate was 78.3% (18/23; 3 complete responses and 15 partial responses). The median duration of response was 17.4 months (median follow-up, 9.4 months), and median time to response was 2.1 months. Median progression-free survival was 24.1 months (median follow-up, 10.3 months), and median overall survival was not reached (median follow-up, 28.4 months). The most common all-grade treatment-emergent adverse events (TEAEs) included fatigue (52.2%, 12/23), diarrhea, and transient, infusion-related hyperglycemia (each 47.8%, 11/23). Nineteen patients (82.6%) had grade 3/4 TEAEs, most commonly transient, infusion-related hyperglycemia and hypertension (each 39.1%, 9/23). TEAEs led to dose reduction or dose interruptions /delays in 9 patients (39.1%) and 18 patients (78.3%), respectively. Patients with activated PI3K/B-cell antigen receptor signaling had improved response rates. Overall, copanlisib demonstrated strong efficacy, with a short time to objective response, improved objective response rate with longer treatment duration, durable responses, and manageable safety, in line with previous reports. These data provide rationale for long-term treatment with copanlisib in patients with relapsed/refractory MZL.
引用
- Panayiotidis P, Follows GA, Mollica L, et al. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. Blood Adv. 2021. PMID: 33560394. doi:10.1182/bloodadvances.2020002910
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。